Methods of treating cancers with therapeutic nanoparticles

Patent metadata

Field	Value
Publication number	US-2017266293-A1
Application number	US-201715603151-A
Country	US
Kind code	A1
Filing date	May 23, 2017
Priority date	Sep 22, 2011
Publication date	Sep 21, 2017
Grant date	—

Abstract

The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles.

First claim

What is claimed is:

1 . A method of treating cervical cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles having a hydrodynamic diameter of about 60 to about 150 nm comprising:
docetaxel and about 10 to about 97 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer, wherein the poly(lactic acid) block has a number average molecular weight of about 15 to 20 kDa and the poly(ethylene)glycol block has a number average molecular weight of about 4 to about 6 kDa; and wherein the cervical cancer is a refractory cancer, and wherein the refractory cancer is refractory to other chemotherapy and/or radiation therapy alone.

2 . The method of claim 1 , wherein the therapeutically effective amount of the nanoparticle composition is about 50 to about 75 mg/m 2 of docetaxel.

3 . The method of claim 2 , wherein the therapeutically effective amount of the nanoparticle composition is about 60 to about 75 mg/m 2 of docetaxel.

4 . The method of claim 2 , wherein the therapeutically effective amount of the nanoparticle composition is about 60 mg/m 2 of docetaxel.

5 . The method of claim 1 , comprising administering the composition about every three weeks to said patient.

6 . The method of claim 1 , wherein the composition is administered by intravenous infusion over about 1 hour.

7 . The method of claim 1 , wherein the therapeutically effective amount of the nanoparticle composition is about 75 mg/m 2 of docetaxel.

8 . The method of claim 1 , wherein the patient had previously been administered another chemotherapeutic agent and/or radiation.

Assignees

• Pfizer

Inventors

• Zale Stephen E
• Troiano Greg
• Ali Mir Mukkaram
• Hrkach Jeff
• Wright James

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/04

  for throat disorders · CPC title

• A61K47/34 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title

• A61P13/08

  of the prostate · CPC title